Haleon (LON:HLN) Trading Up 0.3% – Time to Buy?

Haleon plc (LON:HLN)’s share price rose 0.3% during trading on Wednesday . The stock traded as high as GBX 336.40 and last traded at GBX 334.47. Approximately 36,930,695 shares changed hands during trading, an increase of 25% from the average daily volume of 29,557,242 shares. The stock had previously closed at GBX 333.30.

Wall Street Analyst Weigh In

HLN has been the topic of a number of research analyst reports. Berenberg Bank reaffirmed a “buy” rating and set a GBX 512 price target on shares of Haleon in a research report on Thursday, April 30th. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 price objective on shares of Haleon in a research report on Thursday, April 30th. Finally, Jefferies Financial Group reduced their price target on Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a report on Tuesday, May 5th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of GBX 398.67.

Haleon Stock Performance

The firm has a market cap of £29.59 billion, a price-to-earnings ratio of 18.08, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The stock’s 50 day moving average is GBX 341.99 and its 200 day moving average is GBX 365.25.

Insider Buying and Selling at Haleon

In related news, insider Brian McNamara sold 63,012 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total value of £231,884.16. Corporate insiders own 0.01% of the company’s stock.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.